<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="3160"><DrugName>fluvastatin</DrugName><DrugNamesKey><Name id="42765499">Canef</Name><Name id="42765501">Lescol</Name><Name id="42765503">Lipaxan</Name><Name id="42765502">Lochol</Name><Name id="42765500">Locol</Name><Name id="42754949">fluvastatin</Name></DrugNamesKey><DrugSynonyms><Name><Value>fluvastatin sodium</Value></Name><Name><Value>fluvastatin</Value><Types><Type>BAN</Type><Type>INN</Type></Types></Name><Name><Value>Canef</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Locol</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Lescol</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Lochol</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Lipaxan</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>XU-62-320</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>SRI-62-320</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>fluindostatin</Value></Name><Name><Value>HMG-CoA inhibitor, Sandoz</Value></Name><Name><Value>HMG-CoA inhibitor, Novartis</Value></Name><Name><Value>93957-55-2</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>93957-54-1</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="23137">Novartis AG</CompanyOriginator><CompaniesPrimary><Company id="1013295">Astellas Pharma Inc</Company><Company id="23137">Novartis AG</Company></CompaniesPrimary><CompaniesSecondary><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Company id="14190">AstraZeneca plc</Company><Company id="16881">Astra AB</Company><Company id="20315">Tanabe Seiyaku Co Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="3160" type="Drug"><TargetEntity id="129568" type="siDrug">Fluvastatin sodium</TargetEntity></SourceEntity><SourceEntity id="1013295" type="Company"><TargetEntity id="4295876965" type="organizationId">Astellas Pharma Inc</TargetEntity></SourceEntity><SourceEntity id="1035060" type="Company"><TargetEntity id="4295878022" type="organizationId">Mitsubishi Tanabe Pharma Corp</TargetEntity></SourceEntity><SourceEntity id="14190" type="Company"><TargetEntity id="4295894341" type="organizationId">AstraZeneca PLC</TargetEntity></SourceEntity><SourceEntity id="16881" type="Company"><TargetEntity id="5035884249" type="organizationId">AB Astra Apotekarnes Kemiska Fabriker</TargetEntity></SourceEntity><SourceEntity id="20315" type="Company"><TargetEntity id="4298123051" type="organizationId">Nipro ES Pharma Co Ltd</TargetEntity></SourceEntity><SourceEntity id="23137" type="Company"><TargetEntity id="4295890628" type="organizationId">Novartis AG</TargetEntity></SourceEntity><SourceEntity id="174" type="ciIndication"><TargetEntity id="10020603" type="MEDDRA"></TargetEntity><TargetEntity id="D006937" type="MeSH"></TargetEntity><TargetEntity id="-1478187279" type="omicsDisease"></TargetEntity><TargetEntity id="969" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="175" type="ciIndication"><TargetEntity id="10062060" type="MEDDRA"></TargetEntity><TargetEntity id="D006949" type="MeSH"></TargetEntity><TargetEntity id="-1908196798" type="omicsDisease"></TargetEntity><TargetEntity id="971" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3204" type="ciIndication"><TargetEntity id="970" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="33" type="ciIndication"><TargetEntity id="I70" type="ICD10"></TargetEntity><TargetEntity id="440" type="ICD9"></TargetEntity><TargetEntity id="D050197" type="MeSH"></TargetEntity><TargetEntity id="-848966698" type="omicsDisease"></TargetEntity><TargetEntity id="208" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="584" type="ciIndication"><TargetEntity id="10061227" type="MEDDRA"></TargetEntity><TargetEntity id="D052439" type="MeSH"></TargetEntity><TargetEntity id="-386237446" type="omicsDisease"></TargetEntity><TargetEntity id="2898" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="71" type="Action"><TargetEntity id="693" type="Mechanism">Cholesterol Absorption Inhibitors</TargetEntity></SourceEntity><SourceEntity id="205" type="Action"><TargetEntity id="437" type="Mechanism">HMG-CoA Reductase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00943" type="ciTarget"><TargetEntity id="112452388431563" type="siTarget">3-hydroxy-3-methylglutaryl-coenzyme A reductase</TargetEntity><TargetEntity id="2750" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Familial hypercholesterolemia - US - Dec-1994</FirstLaunched><FirstLaunched>Hyperlipidemia - US - Dec-1994</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="174">Hypercholesterolemia</Indication><Indication id="175">Hyperlipidemia</Indication><Indication id="3204">Familial hypercholesterolemia</Indication><Indication id="33">Atherosclerosis</Indication><Indication id="584">Lipid metabolism disorder</Indication></IndicationsPrimary><ActionsPrimary><Action id="205">HMG CoA reductase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="71">Antihypercholesterolemic agent</Action></ActionsSecondary><Technologies><Technology id="751">Film coating</Technology><Technology id="586">Capsule formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>C10A1</Code><Name>Statins (HMG-CoA reductase inhibitors)</Name></Ephmra><Ephmra><Code>C10A</Code><Name>CHOLESTEROL AND TRIGLYCERIDE REDUCTION PREPARATIONS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-01-02T08:32:41.000Z</LastModificationDate><ChangeDateLast>2018-05-15T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Fluvastatin (Lescol; Lochol) is an HMG-CoA reductase inhibitor codeveloped by &lt;ulink linkID="23137" linkType="Company"&gt;Novartis AG&lt;/ulink&gt; and &lt;ulink linkID="20315" linkType="Company"&gt;Tanabe Seiyaku&lt;/ulink&gt; (now &lt;ulink linkID="1035060" linkType="Company"&gt; Mitsubishi Tanabe Pharma&lt;/ulink&gt;) and now marketed solely by Novartis. In the US the drug is indicated an adjunctive therapy to diet to: reduce elevated TC, LDL-C, Apo B, and TG, and to increase HDL-C in adult patients with primary hypercholesterolemia and mixed dyslipidemia; reduce elevated TC, LDL-C, and Apo B levels in boys and post-menarchal girls, 10 to 16 years of age, with heterozygous familial hypercholesterolemia (HeFH) after failing an adequate trial of diet therapy; reduce the risk of undergoing revascularization procedures in patients with clinically evident CHD; and slow the progression of atherosclerosis in patients with CHD [&lt;ulink linkID="471776" linkType="Reference"&gt;471776&lt;/ulink&gt;]. In the EU, the drug is indicated for the treatment of adults with primary hypercholesterolemia or mixed dyslipidemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate; and for the secondary prevention of major adverse cardiac events in adults with coronary heart disease after percutaneous coronary interventions [&lt;ulink linkID="1905183" linkType="Reference"&gt;1905183&lt;/ulink&gt;]. In Japan, the drug is indicated for hypercholesterolemia and familial hypercholesterolemia [&lt;ulink linkID="1905211" linkType="Reference"&gt;1905211&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 1993, the drug was approved in the US for the treatment of hypercholesterolemia and mixed dyslipidemia and launched in the US in 1994 [&lt;ulink linkID="302067" linkType="Reference"&gt;302067&lt;/ulink&gt;], [&lt;ulink linkID="1484863" linkType="Reference"&gt;1484863&lt;/ulink&gt;]; in May 2003, the FDA approved fluvastatin for the secondary prevention of coronary events in patients with coronary heart disease [&lt;ulink linkID="1133019" linkType="Reference"&gt;1133019&lt;/ulink&gt;]. By December 1995, fluvastatin had been launched in Denmark, Norway, Sweden, Germany and the Netherlands [&lt;ulink linkID="217907" linkType="Reference"&gt;217907&lt;/ulink&gt;]; by January 2003,  fluvastatin had been launched in other regions in Europe [&lt;ulink linkID="477293" linkType="Reference"&gt;477293&lt;/ulink&gt;]. In September 1998, launch took place in Japan [&lt;ulink linkID="302067" linkType="Reference"&gt;302067&lt;/ulink&gt;], [&lt;ulink linkID="510850" linkType="Reference"&gt;510850&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Novartis also markets an &lt;ulink linkID="91576" linkType="Drug"&gt;extended-release formulation&lt;/ulink&gt; (Lescol XL; Nandovar XL) of  fluvastatin for the treatment of hypercholesterolemia and mixed dyslipidemia.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;Patent protection for fluvastatin expired in the US on June 12,  2012 (&lt;ulink linkID="IN2159506" linkType="Patent"&gt;US-05356896&lt;/ulink&gt;) following a 6-month pediatric extension. Formulation patents for fluvastatin  expired from 2012 [&lt;ulink linkID="1164651" linkType="Reference"&gt;1164651&lt;/ulink&gt;], [&lt;ulink linkID="1271345" linkType="Reference"&gt;1271345&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2008, &lt;ulink linkID="18439" linkType="Company"&gt;Mylan&lt;/ulink&gt; confirmed that is was being sued by Novartis over its ANDA filing for fluvastatin capsules (20 and 40 mg), which contained a Paragraph IV certification relating to &lt;ulink linkID="IN2159381" linkType="Patent"&gt;US-05354772&lt;/ulink&gt;. Mylan filed the ANDA with the FDA in June 2008 [&lt;ulink linkID="954712" linkType="Reference"&gt;954712&lt;/ulink&gt;]. By April 2012, Mylan and Novartis had reached a settlement and license agreement whereby Mylan could launch its generic prior to the expiration of US-05356896's pediatric exclusivity in June 12, 2012. In April 2012, the FDA granted final approval for Mylan's generic fluvastatin (20 and 40 mg capsules), and the drug was launched immediately [&lt;ulink linkID="1279945" linkType="Reference"&gt;1279945&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In 2010, &lt;ulink linkID="20348" linkType="Company"&gt;Teva Pharmaceutical Industries&lt;/ulink&gt; received tentative FDA approval for its generic fluvastatin  capsules [&lt;ulink linkID="1172340" linkType="Reference"&gt;1172340&lt;/ulink&gt;]; final FDA approval was granted for Teva's 20 and 40 mg generic fluvastatin capsules in June 2012 [&lt;ulink linkID="1308894" linkType="Reference"&gt;1308894&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;Patent protection for fluvastatin (&lt;ulink linkID="IN1782835" linkType="Patent"&gt;EP-00114027&lt;/ulink&gt;) expired in major EU markets in August 2008 [&lt;ulink linkID="1164651" linkType="Reference"&gt;1164651&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By January 2011, several generic manufacturers had launched generic fluvastatin products in European markets [&lt;ulink linkID="1164651" linkType="Reference"&gt;1164651&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;By January 2011, fluvastatin generics had been launched in Japan [&lt;ulink linkID="1164650" linkType="Reference"&gt;1164650&lt;/ulink&gt;], [&lt;ulink linkID="1164651" linkType="Reference"&gt;1164651&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In December 2018, &lt;ulink linkID="1066156" linkType="Company"&gt;Beijing Sciecure Pharmaceutical&lt;/ulink&gt; submitted an ANDA filing for its generic version of fluvastatin sustained release tablets in China [&lt;ulink linkID="2100481" linkType="Reference"&gt;2100481&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In December 1993, the drug was approved in the US for the treatment of hypercholesterolemia and mixed dyslipidemia and launched in the US in 1994 [&lt;ulink linkID="302067" linkType="Reference"&gt;302067&lt;/ulink&gt;] [&lt;ulink linkID="1484863" linkType="Reference"&gt;1484863&lt;/ulink&gt;]. In November 1996, fluvastatin was filed for approval in the US for slowing  the progression of coronary atherosclerosis in patients with coronary heart disease [&lt;ulink linkID="226579" linkType="Reference"&gt;226579&lt;/ulink&gt;]; in May 2003, the FDA approved the drug for the secondary prevention of coronary events in patients with coronary heart disease [&lt;ulink linkID="1133019" linkType="Reference"&gt;1133019&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In March 1994, the drug was launched in Switzerland [&lt;ulink linkID="1593721" linkType="Reference"&gt;1593721&lt;/ulink&gt;]. By December 1995, fluvastatin had been launched by Novartis and licensee &lt;ulink linkID="16881" linkType="Company"&gt;Astra AB&lt;/ulink&gt; (now &lt;ulink linkID="14190" linkType="Company"&gt;AstraZeneca&lt;/ulink&gt;) in Denmark, Norway, Sweden, Germany and the Netherlands [&lt;ulink linkID="217907" linkType="Reference"&gt;217907&lt;/ulink&gt;]. By January 2003,  fluvastatin had been launched in other regions in Europe [&lt;ulink linkID="477293" linkType="Reference"&gt;477293&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;By May 1995, fluvastatin had been filed for approval for hyperlipidemia and slowing the progression of atherosclerosis [&lt;ulink linkID="212110" linkType="Reference"&gt;212110&lt;/ulink&gt;]. In September 1998, launch took place in Japan [&lt;ulink linkID="302067" linkType="Reference"&gt;302067&lt;/ulink&gt;], [&lt;ulink linkID="510850" linkType="Reference"&gt;510850&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;It was assumed that the drug was launched in China shortly after its approval there in 2001  [&lt;ulink linkID="989520" linkType="Reference"&gt;989520&lt;/ulink&gt;], [&lt;ulink linkID="1514150" linkType="Reference"&gt;1514150&lt;/ulink&gt;], [&lt;ulink linkID="1516990" linkType="Reference"&gt;1516990&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;By December 1995, fluvastatin had been launched in Canada for hyperlipidemia [&lt;ulink linkID="217907" linkType="Reference"&gt;217907&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;By December 1995, fluvastatin had been launched in Australia for hyperlipidemia [&lt;ulink linkID="217907" linkType="Reference"&gt;217907&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 1995, fluvastatin had been launched in New Zealand for hyperlipidemia [&lt;ulink linkID="217907" linkType="Reference"&gt;217907&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 1996, the drug was approved in Taiwan; it was assumed that launch took place shortly after approval [&lt;ulink linkID="1509402" linkType="Reference"&gt;1509402&lt;/ulink&gt;], [&lt;ulink linkID="1516987" linkType="Reference"&gt;1516987&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;In June 2005, a 12-week, randomized, double-blind, active control phase III trial (&lt;ulink linkID="5884" linkType="Protocol"&gt;NCT00136799&lt;/ulink&gt;) was initiated in China in subjects (expected n = 320) with mixed dyslipidemia or primary hypercholesterolemia. The trial was to evaluate the safety and tolerability of fluvastatin (80 mg) in a Chinese population. The primary endpoint was percentage change from baseline in low density lipoprotein cholesterol and secondary endpoints included percentage change from baseline in total cholesterol, high density lipoprotein cholesterol and total triglycerides. By February 2007, the study had been completed [&lt;ulink linkID="889583" linkType="Reference"&gt;889583&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2004, a 5-week, randomized, double-blind, placebo-controlled phase IV trial (&lt;ulink linkID="39303" linkType="Protocol"&gt;NCT00138528&lt;/ulink&gt;) was initiated in Germany in subjects (expected n = 50) with metabolic syndrome. The primary endpoint was percentage change from baseline in circulating marker of inflammation (C-reactive protein), and secondary endpoints included change from baseline in low density lipoprotein cholesterol, non-high density lipoprotein cholesterol, high density lipoprotein cholesterol and oxidized low density lipoprotein cholesterol. By March 2008, the study had been completed [&lt;ulink linkID="889492" linkType="Reference"&gt;889492&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2004, a randomized, open-label phase IV trial (&lt;ulink linkID="20840" linkType="Protocol"&gt;NCT00171327&lt;/ulink&gt;) was initiated in the Russian Federation in subjects (expected n = 100) with mild to moderate hypertension, dyslipidemia and decreased vascular dilatation. The subjects were to receive fluvastatin (80 mg) or &lt;ulink linkID="2773" linkType="Drug"&gt;valsartan&lt;/ulink&gt; (160 mg). The primary endpoint was percentage change from baseline in brachial artery flow-mediated vasodilation after 8 weeks. By March 2008, the study had been completed [&lt;ulink linkID="889492" linkType="Reference"&gt;889492&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2003, a randomized, double-blind, placebo-controlled phase IV trial (&lt;ulink linkID="47845" linkType="Protocol"&gt;NCT00171275&lt;/ulink&gt;) was initiated in the Czech Republic in subjects (expected n = 1000) with acute coronary syndrome. Fluvastatin or placebo was administered to subjects shortly after the occurrence of a coronary event. The primary endpoint was change from baseline in markers of inflammation after 4 and 52 weeks. The study was completed in March 2006 [&lt;ulink linkID="889589" linkType="Reference"&gt;889589&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2003, results from the ALERT (Assessment of Lescol in Renal Transplantation) study demonstrated fluvastatin therapy was associated with reduced cardiac events and could be used effectively and safely to lower cholesterol in kidney transplant patients [&lt;ulink linkID="658369" linkType="Reference"&gt;658369&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2002, results from the LIPS demonstrated fluvastatin reduced the risk of fatal and serious non-fatal cardiac events by 22% in patients with average cholesterol levels undergoing a first angioplasty. Diabetic patients experienced a 47% risk reduction, and patients with multivessel disease experienced a 34% risk reduction [&lt;ulink linkID="658372" linkType="Reference"&gt;658372&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In 1998, the FAME outcomes study was initiated, which was to evaluate the prophylactic efficacy of fluvastatin against major vascular events in an at-risk elderly population with moderate hypercholesterolemia. However, the trial was halted in January 2000 due to a reallocation of resources within Novartis [&lt;ulink linkID="1133016" linkType="Reference"&gt;1133016&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 1997, the LCAS trial demonstrated fluvastatin slowed the progression (in some cases, regression) of coronary heart disease (CHD) in patients with mild to moderate low density lipoprotein cholesterol (LDL-C) elevation [&lt;ulink linkID="258076" linkType="Reference"&gt;258076&lt;/ulink&gt;].&lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;Positive phase III trial results were presented at AHS in 1996 [&lt;ulink linkID="224860" linkType="Reference"&gt;224860&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 1994, a randomized, double-blind, placebo-controlled trial had been initiated in Sweden to assess use of   fluvastatin (40 mg once daily) and low-dose metoprolol CR/XL (25 mg once daily)  in subjects (expected n = 793) with plaque in the right carotid artery but no symptoms of carotid artery disease. The primary endpoint was change in mean intima-media thickness (IMT) in the common carotid artery (CCA) and maximal IMT in the bulb. In April 2001, data were published; Fluvastatin but not metoprolol CR/XL reduced the rate of progression of mean IMT in the CCA compared with placebo after 36 months (mean difference between groups, −0.009 mm/y; P=0.002). Metoprolol CR/X but not fluvastatin reduced the progression of maximum IMT in the carotid bulb  [&lt;ulink linkID="1369087" linkType="Reference"&gt;1369087&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In 1991, a summary of data from a number of clinical trials (2800 patients, 1000 followed for more than 1 year) was presented at the ninth International Symposium on Atherosclerosis. These results suggested that the compound was an effective hypolipidemic agent  - LDL cholesterol was reduced by 5 to 28% at 5 to 40 mg per day. Such reductions were comparable to those achieved with &lt;ulink linkID="44300" linkType="Drug"&gt;lovastatin&lt;/ulink&gt; (19 to 33% at 10 to 40 mg per day) and &lt;ulink linkID="4155" linkType="Drug"&gt;pravastatin&lt;/ulink&gt; (19 to 32% at 10 to 40 mg per day) but less than those generally seen with &lt;ulink linkID="44313" linkType="Drug"&gt;simvastatin&lt;/ulink&gt;, the most potent inhibitor on the market (28 to 41% at 10 to 40 mg per day). Results from four separate trial groups were also presented at the symposium. These included a study examining combination therapy with cholestyramine, which showed some synergistic effects in terms of LDL-cholesterol reduction (up to 45%) and a small comparative study with benzafibrate, suggesting that fluvastatin is the superior LDL- lowering agent. Sandoz reported an analysis of ADRs from trials involving 800 patients, showing a low incidence of side effects, comparable to those seen with placebo: (7.9% headache; 5.8% diarrhea; 2.8% nausea; 2.5% constipation; 2.1% insomnia; 0.9% myalgia; 0.8% vomiting) [&lt;ulink linkID="50038" linkType="Reference"&gt;50038&lt;/ulink&gt;], [&lt;ulink linkID="50039" linkType="Reference"&gt;50039&lt;/ulink&gt;], [&lt;ulink linkID="50043" linkType="Reference"&gt;50043&lt;/ulink&gt;], [&lt;ulink linkID="50048" linkType="Reference"&gt;50048&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;OTHER STUDIES&lt;/subtitle&gt;In November 2015, clinical data were presented from a multicenter (5 centers), randomized, 12-month controlled study which evaluated the effect of fluvastatin (Lescol XR) treatment on proteinuria in 133 diabetic patients with chronic kidney disease at ASN's Kidney Week 2015 in San Diego, CA. All patients received fluvastatin (20 mg) for 6 months and at month 6 patients (n = 75) were randomized to either continue to receive fluvastatin (study A) or discontinue fluvastatin (study B) for additional 6 months. No significant reduction in urinary protein and microalbumin excretion was observed during the treatment and no significant differences were noted between groups [&lt;ulink linkID="1708488" linkType="Reference"&gt;1708488&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;The compound is a potent inhibitor in vitro (more active than &lt;ulink linkID="44300" linkType="Drug"&gt;lovastatin&lt;/ulink&gt;) and in vivo in several animal models [&lt;ulink linkID="224860" linkType="Reference"&gt;224860&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><ExpertReview>&lt;para&gt;&lt;ulink linkType="Drug" linkID="3160"&gt;Fluvastatin&lt;/ulink&gt; is likely to be the first totally synthetic HMG-CoA reductase inhibitor to reach the market (it is in late Phase III trials). It was developed as part of an elegant series of SAR studies conducted at the Sandoz Institute and recently described by Kathawala [&lt;ulink linkType="reference" linkID="14042"&gt;14042&lt;/ulink&gt;]. The compound is a potent inhibitor in vitro (more active than &lt;ulink linkType="Drug" linkID="44300"&gt;lovastatin&lt;/ulink&gt;) and in vivo in several animal models. &lt;/para&gt;&lt;para&gt;A summary of the experience to date gained from a number of clinical trials (2,800 patients, 1,000 followed for more than 1 year) was presented by R Levy of Sandoz at the recent 9th International Symposium on Atherosclerosis.  These suggest that the compound is an effective hypolipidaemic agent  - LDL cholesterol is reduced by 5-28% at 5-40mg per day. Such reductions are comparable to those achieved with &lt;ulink linkType="Drug" linkID="44300"&gt;lovastatin&lt;/ulink&gt; (19-33 % at 10-40mg per day) and &lt;ulink linkType="Drug" linkID="4155"&gt;pravastatin&lt;/ulink&gt; (19 to 32 % at 10-40mg per day) but less than those generally seen with &lt;ulink linkType="Drug" linkID="44313"&gt;simvastatin&lt;/ulink&gt;, the most potent inhibitor on the market (28-41 % at 10-40mg per day). However, it should be noted that the results of direct comparative trials with these agents, on which any sound clinical choice should be based, are not yet available.&lt;/para&gt;&lt;para&gt;Results from four separate trial groups [50038, 50039, 50043, 50048] were also presented at the Symposium. These included a study examining combination therapy with cholestyramine which, as with other statins, showed some synergistic effects in terms of LDL-cholesterol reduction (up to 45 %), and a small comparative study with benzafibrate, suggesting that &lt;ulink linkType="Drug" linkID="3160"&gt;fluvastatin&lt;/ulink&gt; is the superior LDL- lowering agent, as might be expected from trials with other HMGR inhibitors. Sandoz reported an analysis of ADRs from trials involving 800 patients, showing a low incidence of side-effects, comparable to those seen with placebo: (7.9 % headache; 5.8 % diarrhoea; 2.8 % nausea; 2.5 % constipation; 2.1 % insomnia; 0.9 % myalgia; 0.8 % vomiting). &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;EXPERT OPINION&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;Sandoz' &lt;ulink linkType="Drug" linkID="3160"&gt;fluvastatin&lt;/ulink&gt; should be the fourth HMG-CoA reductase inhibitor to reach the market, with launches expected in Europe in 1993, the US in 1994 and Japan in 1997. Analysts sales estimates are in the $100-250m range. It seems from a recent news item (Scrip (1991), 1663, p24) that the company's pitch may be based on a possible `superior metabolic profile' on the grounds that there is extensive first pass metabolism by the liver, efficient biliary excretion and lack of circulating metabolites or CNS uptake - the inference being that this may reduce the possibility of side effects. To date, no evidence has published in support of this contention. In terms of LDL- cholesterol lowering, it appears to offer no advantage over the currently marketed HMGR inhibitors such as &lt;ulink linkType="Drug" linkID="44313"&gt;simvastatin&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="4155"&gt;pravastatin&lt;/ulink&gt;. A recent paper from Bristol-Myers [&lt;ulink linkType="reference" linkID="8584"&gt;8584&lt;/ulink&gt;] comparing the tissue selectivity of its lead compound (BMY-21950) with &lt;ulink linkType="Drug" linkID="3160"&gt;fluvastatin&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="44300"&gt;lovastatin&lt;/ulink&gt; concludes that its compound, like &lt;ulink linkType="Drug" linkID="4155"&gt;pravastatin&lt;/ulink&gt;, has a high degree of liver selectivity based upon observable differential inhibition sensitivities in different tissues, whereas both &lt;ulink linkType="Drug" linkID="3160"&gt;fluvastatin&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="44300"&gt;lovastatin&lt;/ulink&gt; are potent HMGR inhibitors in all tissues tested. &lt;br/&gt;The Lipoprotein and Coronary Atherosclerosis Study (LCAS) has been initiated to investigate the effects of &lt;ulink linkType="Drug" linkID="3160"&gt;fluvastatin&lt;/ulink&gt; in atherosclerosis plaque regression.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3204">Familial hypercholesterolemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1994-12-31T00:00:00.000Z</StatusDate><Source id="302067" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1996-12-31T00:00:00.000Z</StatusDate><Source id="1509402" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="1516990" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="33">Atherosclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-03-01T00:00:00.000Z</StatusDate><Source id="867928" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1995-12-01T00:00:00.000Z</StatusDate><Source id="217907" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1995-12-01T00:00:00.000Z</StatusDate><Source id="217907" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1995-12-01T00:00:00.000Z</StatusDate><Source id="217907" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1994-12-31T00:00:00.000Z</StatusDate><Source id="302067" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1995-12-01T00:00:00.000Z</StatusDate><Source id="217907" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-03-01T00:00:00.000Z</StatusDate><Source id="867928" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="33">Atherosclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-05-31T00:00:00.000Z</StatusDate><Source id="1133019" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-09-12T00:00:00.000Z</StatusDate><Source id="584773" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1995-12-01T00:00:00.000Z</StatusDate><Source id="217907" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="33">Atherosclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-03-01T00:00:00.000Z</StatusDate><Source id="867928" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="175">Hyperlipidemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-08-31T00:00:00.000Z</StatusDate><Source id="584773" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="584">Lipid metabolism disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-08-31T00:00:00.000Z</StatusDate><Source id="584773" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="175">Hyperlipidemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-03-01T00:00:00.000Z</StatusDate><Source id="867928" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="175">Hyperlipidemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-08-31T00:00:00.000Z</StatusDate><Source id="584773" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="175">Hyperlipidemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-08-31T00:00:00.000Z</StatusDate><Source id="584773" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="174">Hypercholesterolemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-08-31T00:00:00.000Z</StatusDate><Source id="584773" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-09-12T00:00:00.000Z</StatusDate><Source id="584773" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="16881">Astra AB</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><Source id="167497" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3204">Familial hypercholesterolemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1993-12-31T00:00:00.000Z</StatusDate><Source id="1484863" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16881">Astra AB</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><Source id="167497" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16881">Astra AB</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><Source id="167497" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-12-31T00:00:00.000Z</StatusDate><Source id="1516990" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1996-04-16T00:00:00.000Z</StatusDate><Source id="1516987" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="33">Atherosclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1996-11-26T00:00:00.000Z</StatusDate><Source id="226579" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1993-12-31T00:00:00.000Z</StatusDate><Source id="1484863" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16881">Astra AB</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1995-12-01T00:00:00.000Z</StatusDate><Source id="217907" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16881">Astra AB</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1995-12-01T00:00:00.000Z</StatusDate><Source id="217907" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16881">Astra AB</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1995-12-01T00:00:00.000Z</StatusDate><Source id="217907" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16881">Astra AB</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1995-12-01T00:00:00.000Z</StatusDate><Source id="217907" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-04-06T00:00:00.000Z</StatusDate><Source id="318363" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-04-06T00:00:00.000Z</StatusDate><Source id="318363" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-04-06T00:00:00.000Z</StatusDate><Source id="318363" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="33">Atherosclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-05-31T00:00:00.000Z</StatusDate><Source id="1133019" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16881">Astra AB</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1995-12-01T00:00:00.000Z</StatusDate><Source id="217907" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20315">Tanabe Seiyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1995-05-01T00:00:00.000Z</StatusDate><Source id="212110" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20315">Tanabe Seiyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="33">Atherosclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1995-05-01T00:00:00.000Z</StatusDate><Source id="212110" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20315">Tanabe Seiyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="33">Atherosclerosis</Indication><Source id="167497" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20315">Tanabe Seiyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><Source id="167497" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1998-10-01T00:00:00.000Z</StatusDate><Source id="836299" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="33">Atherosclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1998-10-01T00:00:00.000Z</StatusDate><Source id="836299" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20315">Tanabe Seiyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1998-10-01T00:00:00.000Z</StatusDate><Source id="302067" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20315">Tanabe Seiyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="33">Atherosclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1998-10-01T00:00:00.000Z</StatusDate><Source id="302067" type="SERIAL"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00943"><Name>HMG CoA reductase</Name><SwissprotNumbers><Swissprot>O08424</Swissprot><Swissprot>O24594</Swissprot><Swissprot>O26662</Swissprot><Swissprot>O28538</Swissprot><Swissprot>O51628</Swissprot><Swissprot>O59469</Swissprot><Swissprot>O64966</Swissprot><Swissprot>O64967</Swissprot><Swissprot>O74164</Swissprot><Swissprot>O76819</Swissprot><Swissprot>P00347</Swissprot><Swissprot>P04035</Swissprot><Swissprot>P09610</Swissprot><Swissprot>P12683</Swissprot><Swissprot>P12684</Swissprot><Swissprot>P13702</Swissprot><Swissprot>P14773</Swissprot><Swissprot>P14891</Swissprot><Swissprot>P16237</Swissprot><Swissprot>P16393</Swissprot><Swissprot>P20715</Swissprot><Swissprot>P29057</Swissprot><Swissprot>P29058</Swissprot><Swissprot>P34135</Swissprot><Swissprot>P34136</Swissprot><Swissprot>P43256</Swissprot><Swissprot>P48020</Swissprot><Swissprot>P48021</Swissprot><Swissprot>P48022</Swissprot><Swissprot>P51639</Swissprot><Swissprot>P54960</Swissprot><Swissprot>Q00583</Swissprot><Swissprot>Q01237</Swissprot><Swissprot>Q01559</Swissprot><Swissprot>Q03163</Swissprot><Swissprot>Q0DY59</Swissprot><Swissprot>Q10283</Swissprot><Swissprot>Q12577</Swissprot><Swissprot>Q12649</Swissprot><Swissprot>Q29512</Swissprot><Swissprot>Q41437</Swissprot><Swissprot>Q41438</Swissprot><Swissprot>Q58116</Swissprot><Swissprot>Q59468</Swissprot><Swissprot>Q5R6N3</Swissprot><Swissprot>Q9V1R3</Swissprot><Swissprot>Q9XEL8</Swissprot><Swissprot>Q9XHL5</Swissprot><Swissprot>Q9Y7D2</Swissprot><Swissprot>Q9YAS4</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2100481" linkType="reference" linkID="2100481"&gt;2100481&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1009547">Sanofi SA</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1013295">Astellas Pharma Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1022450">Mitsubishi Chemical Holdings Corp</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="14190">AstraZeneca plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="17058">Bausch Health Companies Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="23137">Novartis AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>7</CountTotal></Company><Company><Company id="27561">Sun Pharmaceutical Industries Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="28355">GlaxoSmithKline plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>5</CountActive><CountInactive>1</CountInactive><CountTotal>6</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CC(C)n1c2ccccc2c(c1/C=C/[C@@H](C[C@@H](CC(=O)[O-])O)O)c3ccc(cc3)F.[Na+]</Smiles><Smiles>CC(C)n1c2ccccc2c(c1/C=C/[C@@H](C[C@@H](CC(=O)O)O)O)c3ccc(cc3)F</Smiles></StructureSmiles><Deals><Deal id="121452" title="Sandoz Pharma and Astra to comarket fluvastin in Nordic countries, Australia, the Netherlands, Mexico, New Zealand and Germany "></Deal><Deal id="121453" title="Novartis and Tanabe Seiyaku to comarket fluvastatin in Japan"></Deal><Deal id="121455" title="HMR and Sandoz to cross-license promotions rights to fluvastatin and vigabatrin in the US "></Deal><Deal id="121462" title="Reliant to promote Novartis' Lescol in the US"></Deal><Deal id="121466" title="Amylin and Reliant to copromote Lescol in the US"></Deal><Deal id="121469" title="Biovail to promote Novartis' Lescol in Canada"></Deal><Deal id="121470" title="Klinge Pharma to comarket Novartis' fluvastatin in Germany"></Deal><Deal id="162282" title="Sun Pharma to acquire Japanese manufacturing and marketing rights for 14 branded products from Novartis     "></Deal></Deals><PatentFamilies><PatentFamily id="1009936" number="US-20090275551" title="Fluvastatin for the treatment of patients with a history of muscle related side effects with other statins"></PatentFamily><PatentFamily id="1014737" number="EP-01919466" title="Formulations for treatment of lipoprotein abnormalities comprising a statin and a methylnicotinamide derivative"></PatentFamily><PatentFamily id="1020266" number="WO-00197752" title="Compositions And Methods For Modulating Muscle Cell And Tissue Contractility"></PatentFamily><PatentFamily id="1027513" number="US-07241800" title="Anhydrous amorphous form of fluvastatin sodium"></PatentFamily><PatentFamily id="1103209" number="CN-101215297" title="Statin-bisphosphonate coupling compound, preparation method and application thereof"></PatentFamily><PatentFamily id="1118411" number="IN-200400764" title="Process for preparation of intermediates of fluvastatin"></PatentFamily><PatentFamily id="1119712" number="WO-2012098048" title="Process for the preparation of diol sulfones"></PatentFamily><PatentFamily id="1120326" number="IN-200602137" title="Stabilized fluvastatin compositions has fluvastatin coated with pharmaceutically acceptable polymer"></PatentFamily><PatentFamily id="1144709" number="WO-2007051007" title="Combination of organic compounds"></PatentFamily><PatentFamily id="1157004" number="RU-02338530" title="Method of correction of thrombocytopathy at persons with metabolic syndrome"></PatentFamily><PatentFamily id="1164775" number="WO-2007100894" title="Fluvastatin sodium novel forms and preparation therof"></PatentFamily><PatentFamily id="1165611" number="WO-00203977" title="Combinations of statins, estrogenic agents and optionally estrogens"></PatentFamily><PatentFamily id="1166147" number="WO-00215892" title="Combinations"></PatentFamily><PatentFamily id="1167173" number="CN-01651085" title="Composition comprising aspirin and statin, its preparation and application"></PatentFamily><PatentFamily id="1193557" number="IN-200701266" title="Manufacture of fluvastatin intermediate, involves subjecting indole intermediate to cyclization process using hydrated zinc chloride in presence of alcoholic solvent"></PatentFamily><PatentFamily id="1194437" number="IN-00286818" title="Statin loaded brain permeable nanoparticles and method of preparation"></PatentFamily><PatentFamily id="1217192" number="WO-2006090256" title="Process for the preparation of N-methyl anilino acrolein"></PatentFamily><PatentFamily id="1234791" number="WO-2004113291" title="Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXVIII, processes for preparing them, compositions containing them and methods of using them"></PatentFamily><PatentFamily id="123672" number="EP-01847529" title="Process for the preparation of fluvastatin sodium salt"></PatentFamily><PatentFamily id="1247594" number="WO-2007129290" title="Statins for the treatment of viral influenza infections"></PatentFamily><PatentFamily id="1280935" number="WO-09901126" title="Pharmaceutical compositions comprising Alkanoyl L-Carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism."></PatentFamily><PatentFamily id="128299" number="EP-01905424" title="Process for the preparation of a pharmaceutical composition comprising stabilized statin particles"></PatentFamily><PatentFamily id="1322767" number="WO-2005037787" title="Crystalline form of fluvastatin sodium"></PatentFamily><PatentFamily id="1340431" number="IN-200600461" title="Process for preparation of fluvastatin sodium using trialkyl borane"></PatentFamily><PatentFamily id="134633" number="US-06534537" title="Use of HMG-CoA reductase inhibitors to prevent and treat BPH"></PatentFamily><PatentFamily id="1363118" number="WO-2004096765" title="A novel crystalline polymorph of fluvastatin sodium and a process for preparing it"></PatentFamily><PatentFamily id="1383948" number="WO-09825460" title="Compositions and methods for stimulating bone growth."></PatentFamily><PatentFamily id="1397721" number="WO-2005019170" title="Novel process for preparation of 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1h-indol-2-yl]-3, 5-dihydroxy-6-heptenoic acid sodium salt"></PatentFamily><PatentFamily id="1400494" number="WO-2006105643" title="Stabilized pharmaceutical compositions comprising an hmg-coa reductase inhibitor"></PatentFamily><PatentFamily id="1414348" number="IN-200600462" title="Process for preparation of fluvastatin sodium has formula that is purified using two or more polar organic solvents, and hydrolyzed to fluvastatin or salt then separated from the reaction mass"></PatentFamily><PatentFamily id="1415607" number="IN-200700781" title="Pharmaceutical compositions comprising fluvastatin and glycine and calcium carbonate"></PatentFamily><PatentFamily id="1427783" number="JP-10226644" title="Medicinal Composition"></PatentFamily><PatentFamily id="1458441" number="CN-101618215" title="A medicinal composition containing calcium antagonist, AT-II receptor antagonist and statins"></PatentFamily><PatentFamily id="1460325" number="WO-00176573" title="Combination of organic compounds"></PatentFamily><PatentFamily id="1468908" number="WO-03105837" title="Calcium salts of indole derived statins"></PatentFamily><PatentFamily id="1484798" number="CN-102188421" title="Fluvastatin preparation without containing stabilizing agent"></PatentFamily><PatentFamily id="1490416" number="IN-200601784" title="Process for preparation of stabilized fluvastatin composition"></PatentFamily><PatentFamily id="1512705" number="WO-2006035286" title="Process for preparating enantiomerically pure fluvastatin sodium and a novel polymorphic form thereof"></PatentFamily><PatentFamily id="1512763" number="WO-2006038219" title="Process for the preparation of amorphous fluvastatin sodium"></PatentFamily><PatentFamily id="153305" number="JP-05506415" title="Hmg-coa reductase inhibitor containing oral solid formulation"></PatentFamily><PatentFamily id="156183" number="IN-200400041" title="Process for manufacturing thermally stable novel form of fluvastatin sodium"></PatentFamily><PatentFamily id="156771" number="WO-2010117233" title="Stable pharmaceutical composition containing fluvastatin and method for manufacturing the same"></PatentFamily><PatentFamily id="1585981" number="WO-2005046677" title="Additional pharmaceutical use"></PatentFamily><PatentFamily id="1604069" number="WO-00139770" title="Use Of Hmg-Coa Reductase Inhibitors For Treating Seborrhea"></PatentFamily><PatentFamily id="1607547" number="WO-00236563" title="Crystalline forms of fluvastatin sodium"></PatentFamily><PatentFamily id="1613080" number="WO-2004094343" title="Novel process for stereoselective reduction of ß-ketoesters"></PatentFamily><PatentFamily id="1621563" number="WO-2007089787" title="Compositions and methods for treating cardiovascular, cerebrovascular and other vascular disease patients"></PatentFamily><PatentFamily id="1626510" number="WO-2011117875" title="Salts of fluvastatin and process for the preparation of substantially amorphous fluvastatin sodium"></PatentFamily><PatentFamily id="1629024" number="WO-2012032534" title="Furanose derivatives and their applications in synthesis of statins"></PatentFamily><PatentFamily id="1636207" number="IN-00250249" title="Modified release pharmaceutical formulation containing fluvastatin sodium"></PatentFamily><PatentFamily id="1636598" number="IN-200400065" title="Modified release dosage form of fluvastatin sodium"></PatentFamily><PatentFamily id="1637649" number="IN-200700782" title="Pharmaceutical compositions comprising fluvastatin and stabilizer"></PatentFamily><PatentFamily id="1657672" number="WO-00232408" title="Compositions"></PatentFamily><PatentFamily id="1689211" number="WO-2007079916" title="Combination of triazine derivatives and HMG-CoA reductase  inhibitors."></PatentFamily><PatentFamily id="1710702" number="IN-00244479" title="Immediate release pharmaceutical formulation containing fluvastatin sodium"></PatentFamily><PatentFamily id="1715443" number="EP-00244364" title="Preparation Of Olefinic Compounds"></PatentFamily><PatentFamily id="1726700" number="WO-00137831" title="Pharmaceutical combination comprising separate dosage forms in a compliance package of an inhibitor of HMG CoA reductase and fibric acid derivative"></PatentFamily><PatentFamily id="1738003" number="WO-2008057048" title="Nano &amp;amp; micro-sized particles of statin compounds and process for forming same"></PatentFamily><PatentFamily id="1752231" number="WO-2004080963" title="Process for the preparation of indole derivatives by enzymatic acylation"></PatentFamily><PatentFamily id="1757271" number="WO-00018718" title="Method for producing 6,6-dialkoxy-5-hydroxy-3-oxo-hexanoic acid esters."></PatentFamily><PatentFamily id="1761897" number="WO-2006131933" title="Enzymatic reduction of keto groups in 3-keto-propionic acid derivatives"></PatentFamily><PatentFamily id="1764401" number="RU-02276973" title="Anti-inflammatory ointment with hypolipidemic effect"></PatentFamily><PatentFamily id="1766081" number="WO-03007846" title="Sublingual use of inhibitors in the biosynthesis of cholesterol"></PatentFamily><PatentFamily id="1772892" number="WO-2010118757" title="Improved process for the preparation of fluvastatin and salts thereof"></PatentFamily><PatentFamily id="1777865" number="WO-2009096908" title="Extended-release fluvastatin tablet"></PatentFamily><PatentFamily id="1783144" number="IN-200600463" title="Process for preparation of fluvastatin sodium and its intermediate"></PatentFamily><PatentFamily id="180558" number="US-20060069042" title="Cytochrome P450 2C9 inhibitors"></PatentFamily><PatentFamily id="1809245" number="WO-2006109147" title="Substantially pure amorphous fluvastatin, processes for its preparation and pharmaceutical compositions containing same"></PatentFamily><PatentFamily id="1811306" number="WO-2007137816" title="Process for the preparation of epoxide intermediates for pharmaceutical compounds such as statins"></PatentFamily><PatentFamily id="1823638" number="ES-02321571" title="Solvates fluvastatin sodium and its use as intermediate in obtaining fluvastatin amorphous sodium."></PatentFamily><PatentFamily id="1828185" number="WO-2009048289" title="Pharmaceutical composition for treating hepatitis C virus infection comprising HMG-CoA reductase inhibitor and bile acid"></PatentFamily><PatentFamily id="1856589" number="CN-102309452" title="Fluvastatin sodium liposome solid preparation"></PatentFamily><PatentFamily id="1859916" number="CN-102351776" title="Fluvastatin sodium compound and preparation method thereof"></PatentFamily><PatentFamily id="1907760" number="US-07795451" title="Polymorphic forms of fluvastatin sodium and process for preparing the same"></PatentFamily><PatentFamily id="1909592" number="WO-2009105234" title="Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein"></PatentFamily><PatentFamily id="1913800" number="WO-00193806" title="HMG CoA reductase inhibitors for promoting angiogenesis"></PatentFamily><PatentFamily id="1944636" number="WO-09726874" title="Use of fluvastatin derivatives in skin disease and topical compositions containing them."></PatentFamily><PatentFamily id="1947936" number="WO-09815264" title="Pharmaceutical compositions for sustained release of the HMG-CoA reductase inhibitor fluvastatin."></PatentFamily><PatentFamily id="1955508" number="WO-2005047276" title="Method for the production of statins"></PatentFamily><PatentFamily id="1958475" number="WO-2007031801" title="Improved pharmaceutical composition containing HMG-CoA reductase inhibitor and method for the preparation thereof"></PatentFamily><PatentFamily id="1958530" number="WO-2007039784" title="A novel crystalline polymorph of fluvastatin sodium and process for preparing it"></PatentFamily><PatentFamily id="197054" number="US-20100087462" title="Methods for predicting and detecting intolerance to an hypolipidemic agent"></PatentFamily><PatentFamily id="1975672" number="WO-03070733" title="Novel boronate esters"></PatentFamily><PatentFamily id="1977182" number="WO-02100394" title="Oral pharmaceutical composition containing a statin derivative"></PatentFamily><PatentFamily id="1977396" number="WO-03013512" title="Crystalline forms"></PatentFamily><PatentFamily id="1992988" number="EP-01317251" title="Treated substrate with improved transfer efficiency of topical application"></PatentFamily><PatentFamily id="200200" number="CN-01965843" title="The usage of statin and aspirin in preparing medicine for curing blood hyper-viscosity syndrome"></PatentFamily><PatentFamily id="200244" number="WO-2007134421" title="2-Vinyl indoles, pyrido and azepino indole derivatives, 2-alkynyl indoles, 2-alkynyl benzo[b]furans, their precursors and novel processes for the preparation thereof"></PatentFamily><PatentFamily id="2006276" number="IN-200502674" title="Stabilized pharmaceutical composition comprising fluvastatin"></PatentFamily><PatentFamily id="2020387" number="GB-02329334" title="Cholesterol-lowering agents."></PatentFamily><PatentFamily id="2028221" number="WO-03018555" title="Process for the preparation of indole derivatives"></PatentFamily><PatentFamily id="2048515" number="WO-2004113314" title="Novel boronate esters"></PatentFamily><PatentFamily id="2064037" number="KR-00757256" title="Method for screening drug for treating and preventing alcoholic hepatic disease by using gene maker, whose expression is specifically increased by alcohol intake and which is identified by using suppression subtracted hybridization, and screening kit by using the same"></PatentFamily><PatentFamily id="2066353" number="WO-2009000286" title="Improved pharmaceutical formulation containing an HMG-CoA reductase inhibitor and method for the preparation thereof"></PatentFamily><PatentFamily id="2067587" number="WO-2006021967" title="Process for the preparation of fluvastatin sodium form A."></PatentFamily><PatentFamily id="2070342" number="US-20100009970" title="Compositions and methods for treatment of viral diseases"></PatentFamily><PatentFamily id="2075744" number="US-08318771" title="Method of treatment of nephrogenic diabetes insipidus"></PatentFamily><PatentFamily id="2080051" number="IN-00242826" title="Novel process for preparing fluvastatin sodium amorphous form"></PatentFamily><PatentFamily id="2082758" number="WO-2012116985" title="Treatment of arterial aging by combination of RAAS inhibitor and HMG-CoA reductase inhibitor"></PatentFamily><PatentFamily id="2082932" number="WO-2012116997" title="Treatment of arterial aging by HMG CoA reductase inhibitor"></PatentFamily><PatentFamily id="2084455" number="WO-08402131" title="Analogs of mevalolactone and derivatives thereof, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals."></PatentFamily><PatentFamily id="2094172" number="WO-09749681" title="Polymorphic compounds."></PatentFamily><PatentFamily id="214994" number="CN-101215257" title="Fluvastatin sodium intermediate refining and fluvastatin sodium preparation method"></PatentFamily><PatentFamily id="2150315" number="WO-2011133418" title="Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof"></PatentFamily><PatentFamily id="2167950" number="WO-09815290" title="Pharmaceutical compositions comprising HMG-CoA reductase inhibitors, in particular fluvastatin."></PatentFamily><PatentFamily id="2176467" number="WO-03064392" title="Process for the manufacture of HMG-CoA reductase inhibitors"></PatentFamily><PatentFamily id="2187651" number="DE-10316087" title="Stabilization of polymorphs of fluvastatin sodium in pharmaceutical formulations"></PatentFamily><PatentFamily id="2193026" number="CN-100429202" title="Preparation method of amorphous fluvastatin sodium"></PatentFamily><PatentFamily id="2205036" number="WO-00219990" title="Modified Release Formulation"></PatentFamily><PatentFamily id="2209839" number="WO-2004024165" title="Combination therapy comprising a bisphosphonate and a HMG-CoA reductase inhibitor"></PatentFamily><PatentFamily id="2212074" number="WO-2005063728" title="Process for preparation of statins with high syn to anti ratio"></PatentFamily><PatentFamily id="2215546" number="CN-01978428" title="A preparation method of (3R,5S)-fluvastatin"></PatentFamily><PatentFamily id="2224974" number="IN-200600451" title="Process for preparation of fluvastatin sodium in novel polymorphic form"></PatentFamily><PatentFamily id="2228473" number="IN-200500532" title="Preparation of fluvastatin sodium for preparation of amorphous form of fluvastatin sodium involves forming an aqueous solution of fluvastatin sodium and filtering the same followed by spray drying the filtrate"></PatentFamily><PatentFamily id="2255391" number="WO-2007100822" title="Fluvastatin sodium pharmaceutical compositions"></PatentFamily><PatentFamily id="2256453" number="WO-2008118415" title="Genetic polymorphisms associated with coronary events and drug response, methods of detection and uses thereof"></PatentFamily><PatentFamily id="2270160" number="WO-03080070" title="Combination of organic compounds"></PatentFamily><PatentFamily id="2272325" number="KR-2006092428" title="Composition comprising statin effective for treating imatinib-resistant leukemia"></PatentFamily><PatentFamily id="227235" number="CN-102188706" title="Fluvastatin tablet containing anti-flatulence agent"></PatentFamily><PatentFamily id="2274289" number="WO-00176566" title="Stable Pharmaceutical Compositions Containing 7-Substituted-3,5-Dihydroxyheptanoic Acids Or 7-Substituted-3,5-Dihydroxyheptenoic Acids"></PatentFamily><PatentFamily id="230613" number="IN-200701252" title="Novel preparation of fluvastatin sodium amorphous and fluvastatin ammonium salt"></PatentFamily><PatentFamily id="2325064" number="WO-2004052368" title="Use of certain compounds in treatment of obesity"></PatentFamily><PatentFamily id="2347333" number="WO-00067737" title="Use of HMGCoA reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovacularization"></PatentFamily><PatentFamily id="2363412" number="WO-2007039287" title="Process for the synthesis of HMG-CoA reductase inhibitors"></PatentFamily><PatentFamily id="2364325" number="CN-101250153" title="Technique for preparing fluvastatin sodium crystal system"></PatentFamily><PatentFamily id="2398111" number="CN-102755284" title="Fluvastatin sustained-release drug composition"></PatentFamily><PatentFamily id="2433953" number="CN-102805739" title="Fluvastatin sodium sustained-release coated dropping pills and preparation method thereof"></PatentFamily><PatentFamily id="2472744" number="WO-2013024425" title="Combinations of corroles and statins"></PatentFamily><PatentFamily id="2483913" number="WO-09840375" title="Combination therapy employing ileal bile acid transport inhbiting benzothiepines and HMG Co-A reductase inhibitors."></PatentFamily><PatentFamily id="2486189" number="WO-2013033688" title="Treatment of cancer"></PatentFamily><PatentFamily id="251542" number="WO-00178680" title="Pharmaceutical compositions"></PatentFamily><PatentFamily id="2544686" number="WO-2013083286" title="Treatment of arterial wall by combination of RAAS inhibitor and HMG-CoA reductase inhibitor"></PatentFamily><PatentFamily id="2544834" number="WO-2013083718" title="Process for the preparation of a statin precursor"></PatentFamily><PatentFamily id="2545083" number="WO-2013083719" title="Process for the preparation of a thioprecursor for statins"></PatentFamily><PatentFamily id="2547494" number="CN-103126987" title="Use fluvastatin quantifying aerosol preparation and that of the lung inflammatory disease."></PatentFamily><PatentFamily id="2579182" number="WO-2013172687" title="Novel statin intermediate, and production method for pitavastatin, rosuvastatin, cerivastatin and fluvastatin using same"></PatentFamily><PatentFamily id="2588677" number="CN-103265471" title="Fluvastatin intermediate 3-(4-fluorophenyl)-1-isopropyl-1H-indole preparation method"></PatentFamily><PatentFamily id="2635211" number="CN-103239421" title="Fluvastatin sodium compound capsule and preparation method thereof"></PatentFamily><PatentFamily id="2668584" number="IN-00295909" title="Preparing 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors such as atorvastatin, cerivastatin and rosuvastatin, useful for lowering plasma cholesterol level, comprises converting metal compound into another metal compound"></PatentFamily><PatentFamily id="2682454" number="KR-2014012375" title="Novel preparation method of metabolites of fluvastatin using bacterial cytochrome P450 and composition therefor"></PatentFamily><PatentFamily id="2709597" number="WO-2014051510" title="Statin side effect assessment"></PatentFamily><PatentFamily id="272605" number="WO-03053950" title="New process for the preparation of optically active 2-[6-(substituted alkyl)-1,3-dioxan-4-yl]acetic acid derivatives"></PatentFamily><PatentFamily id="2759676" number="US-09150533" title="Local cochlear application of statins for stimulating neurite regrowth in the cochlea"></PatentFamily><PatentFamily id="2770852" number="WO-2014108795" title="An improved process for the preparation of chiral diol sulfones and statins"></PatentFamily><PatentFamily id="2780782" number="WO-2014119568" title="Use of HMG-CoA reductase inhibitor for treating cisplatin-resistant cancers"></PatentFamily><PatentFamily id="280290" number="US-20090082418" title="Deuterium-enriched fluvastatin"></PatentFamily><PatentFamily id="2824454" number="KR-01538298" title="The novel manufacturing method of the metabolite from the fluvastatin using the bacteria cytochrome P450 and composition thereof"></PatentFamily><PatentFamily id="2884422" number="WO-2015015039" title="Boosting the effect of methotrexate through the combined use with lipophilic statins"></PatentFamily><PatentFamily id="2946232" number="CN-104561142" title="Biological synthesis method of (r)-3-hydroxy glutaric acid monoester"></PatentFamily><PatentFamily id="297644" number="AR-00078995" title="Procedimientos para la preparacion de rosuvastatina calcica"></PatentFamily><PatentFamily id="3030561" number="WO-2015137175" title="Method for producing arylboronic acid ester compound"></PatentFamily><PatentFamily id="3036074" number="WO-2015139512" title="Fluvastatin sodium pharmaceutical composition"></PatentFamily><PatentFamily id="3036203" number="WO-2015139514" title="Fluvastatin sodium composition"></PatentFamily><PatentFamily id="305299" number="WO-2012056509" title="Pharmaceutical composition"></PatentFamily><PatentFamily id="3055918" number="WO-2015158927" title="Compositions and methods to increase production"></PatentFamily><PatentFamily id="30690" number="WO-2005000276" title="Tablet comprising fluvastatin and carmellose calcium"></PatentFamily><PatentFamily id="3130480" number="WO-2016020798" title="Methods for reducing LDL-cholesterol"></PatentFamily><PatentFamily id="3149497" number="GB-201600012" title="Fluvastatin pharmaceutical intermediatez-chloro-1-(4-fluorophenyl) ethanone synthesis method"></PatentFamily><PatentFamily id="3152088" number="WO-2016046799" title="Vaccination of immunocompromised subjects"></PatentFamily><PatentFamily id="3160696" number="WO-2016050904" title="hGH determination for use to guide prevention of a major adverse cardiac event or a cardiovascular disease in a subject"></PatentFamily><PatentFamily id="320503" number="WO-00021525" title="Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent"></PatentFamily><PatentFamily id="3218239" number="CN-105640944" title="Method for reducing sVCAM-1 in type 2 diabetic patients with coronary heart disease"></PatentFamily><PatentFamily id="3267212" number="CN-105803099" title="Kit for checking SLCO1B1, APOE, and LDLR gene site mutation at the same time"></PatentFamily><PatentFamily id="3269510" number="CN-105566318" title="New berberine derivative used for preventing and treating hyperlipemia-related diseases and symptoms"></PatentFamily><PatentFamily id="331854" number="WO-2008033466" title="Compositions and methods for treatment of viral diseases"></PatentFamily><PatentFamily id="3332103" number="CN-102961376" title="Application of HMG-CoA reducing enzyme inhibitor fluvastatin in preparation of lymphoma resistant drug"></PatentFamily><PatentFamily id="3334016" number="CN-103342721" title="One of fluvastatin key intermediate and preparation method"></PatentFamily><PatentFamily id="34480" number="US-20070219208" title="Methods for treating cancer"></PatentFamily><PatentFamily id="35393" number="WO-2008097066" title="An oral sustained-release triple layer tablet"></PatentFamily><PatentFamily id="3540400" number="CN-106344535" title="A anti-isomer micro-porous osmotic pump controlled release tablet and its preparation method"></PatentFamily><PatentFamily id="3566279" number="CN-106431866" title="A fluvastatin medicine intermediate 2 - -1-(4-fluorophenyl) ethanone synthesis method"></PatentFamily><PatentFamily id="3612802" number="CN-106563127" title="An application of statin compound in blocking Ebola virus invading and infecting"></PatentFamily><PatentFamily id="364255" number="WO-2006100686" title="Novel polymorph form G of fluvastatin sodium and process for the preparation thereof"></PatentFamily><PatentFamily id="3683507" number="WO-2017100794" title="Computer-implemented evaluaton of drug safety for a population"></PatentFamily><PatentFamily id="3705800" number="WO-2017117344" title="Fly avatars for cancer and uses thereof"></PatentFamily><PatentFamily id="3707340" number="CN-106905218" title="Fluvastatin sodium preparation method of dehydration metabolite"></PatentFamily><PatentFamily id="3816820" number="WO-2018233595" title="Twin drug-type HMG-CoA reductase inhibitor and synthesis method therefor"></PatentFamily><PatentFamily id="385912" number="WO-09003962" title="Process for the preparation of 7-substituted-hept-6-enoic and -heptanoic acids and derivatives and intermediates thereof"></PatentFamily><PatentFamily id="3892067" number="CN-107441502" title="A carrier compound medicine composite nano-particle"></PatentFamily><PatentFamily id="3897719" number="CN-107496997" title="Disposable composite medicine coating coronary artery probe"></PatentFamily><PatentFamily id="3952696" number="CN-107663164" title="Process for preparing fluvaginone"></PatentFamily><PatentFamily id="3993119" number="CN-107789398" title="A pharmaceutical composition for losing weight and reducing fat and preparation method thereof"></PatentFamily><PatentFamily id="401383" number="WO-2005012279" title="Lactonization process"></PatentFamily><PatentFamily id="402190" number="WO-2008064259" title="Solid dispersion composition"></PatentFamily><PatentFamily id="4096529" number="US-20180169242" title="Pharmaceutical combination for cancer treatment and the therapeutic use thereof"></PatentFamily><PatentFamily id="4209443" number="CN-108553517" title="A pharmaceutical composition for new use for preparing liver-protecting medicine"></PatentFamily><PatentFamily id="421910" number="WO-2006030304" title="Novel forms of fluvastatin sodium, processes for preparation and pharmaceutical compositions thereof"></PatentFamily><PatentFamily id="4423160" number="CN-109395085" title="A pharmaceutical composition for treating neuroblastoma and glioma and application thereof"></PatentFamily><PatentFamily id="45083" number="JP-2007210899" title="Fluvastatin sodium and a method of manufacturing the same"></PatentFamily><PatentFamily id="474944" number="WO-2004027075" title="Chemoenzymatic methods for the synthesis of statins and statin intermediates"></PatentFamily><PatentFamily id="475341" number="EP-01477474" title="Process for the synthesis of n-methyl-n-phenylaminoacrolein"></PatentFamily><PatentFamily id="478661" number="WO-2007023503" title="A process for the preparation of fluvastatin sodium"></PatentFamily><PatentFamily id="493590" number="PL-00386948" title="Method of obtaining amorphous sodium fluvastatine salt"></PatentFamily><PatentFamily id="496110" number="CN-101612403" title="Pharmaceutical composition containing calcium antagonist, ACE inhibitor and statins"></PatentFamily><PatentFamily id="503082" number="WO-2009121152" title="Gene signatures"></PatentFamily><PatentFamily id="569771" number="EP-01911441" title="Controlled release color stable pharmaceutical dosage form of hmg-coa reductase inhibitors, free of alkalizing or buffering agents"></PatentFamily><PatentFamily id="577247" number="WO-2006021326" title="Process and intermediates for the selective synthesis of fluvastatin"></PatentFamily><PatentFamily id="583096" number="WO-2005089804" title="Combinations of HMG-CoA reductase inhibitors and alpha 1 adrenergic receptor antagonists"></PatentFamily><PatentFamily id="58845" number="EP-00547000" title="Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor compound."></PatentFamily><PatentFamily id="590263" number="KR-2010009728" title="The novel manufacturing method of fluvastatin"></PatentFamily><PatentFamily id="594554" number="WO-2012002741" title="Process for the preparation of HMG-CoA reductase inhibitors and intermediates thereof"></PatentFamily><PatentFamily id="621737" number="US-06417374" title="Process for the preparation of beta hydroxy-delta lactone using novel intermediates."></PatentFamily><PatentFamily id="622860" number="WO-2004071431" title="Method and composition for treating neurodegenerative disorders"></PatentFamily><PatentFamily id="626785" number="EP-01818050" title="Stable pharmaceutical compositions comprising a HMG-CoA reductase inhibitor"></PatentFamily><PatentFamily id="638248" number="WO-2009059717" title="Pharmaceutical compositions containing statins and omega-3 fatty acids derivatives and their solid formulations for oral use"></PatentFamily><PatentFamily id="655590" number="WO-02067895" title="Devices And Methods For Cholesterol Management"></PatentFamily><PatentFamily id="657068" number="WO-2006017698" title="Novel statin pharmaceutical compositions and related methods of treatment"></PatentFamily><PatentFamily id="660025" number="WO-2008044243" title="Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof"></PatentFamily><PatentFamily id="662212" number="WO-2007125547" title="Novel process for statins and its pharmaceutically acceptable salts thereof"></PatentFamily><PatentFamily id="675430" number="CN-102526739" title="No valid title"></PatentFamily><PatentFamily id="675879" number="CN-102451161" title="Dispersible tablet containing cholesterol absorption inhibitors and fluvastatin and application thereof"></PatentFamily><PatentFamily id="698546" number="WO-2006064179" title="Process and intermediate compounds useful in the preparation of statins"></PatentFamily><PatentFamily id="718028" number="WO-2009037362" title="Compositions comprising &lt;i&gt;Siraitia grosvenori&lt;/i&gt; extracts and methods for the treatment of infection"></PatentFamily><PatentFamily id="744451" number="IN-200601710" title="Process for preparation of amorphous fluvastatin sodium"></PatentFamily><PatentFamily id="751055" number="IN-200700112" title="Stabilized pharmaceutical composition comprises coating fluvastatin or their salts with polymer in admixture with excipients"></PatentFamily><PatentFamily id="763952" number="WO-00069446" title="Combination therapy for treating hypercholesterolemia"></PatentFamily><PatentFamily id="773850" number="WO-2007016757" title="Stabilized extended release pharmaceutical compositions comprising an HMG-CoA reductase inhibitor"></PatentFamily><PatentFamily id="775190" number="WO-2008069546" title="Oral administrative preparation for treating cardiovascular system disease"></PatentFamily><PatentFamily id="789191" number="WO-00122976" title="Combined Therapies For Atherosclerosis Treatment"></PatentFamily><PatentFamily id="797976" number="WO-00197751" title="New formulation"></PatentFamily><PatentFamily id="803768" number="WO-03074034" title="Medicaments containing active ingredients which lower the level of cholesterol with time-delayed active ingredient release"></PatentFamily><PatentFamily id="805198" number="WO-2008102379" title="Stable sustained release formulations of fluvastatin"></PatentFamily><PatentFamily id="823842" number="KR-2012097613" title="The new manufacturing method of (+)-fluvastatin."></PatentFamily><PatentFamily id="848679" number="WO-2007131517" title="Pharmaceutical formulation containing an HMG-CoA reductase inhibitor and method for the preparation thereof"></PatentFamily><PatentFamily id="874488" number="US-20020058026" title="Hmg coa reductase inhibitor medications combined wih coenzyme q-10"></PatentFamily><PatentFamily id="894627" number="IN-200700792" title="Industrial process for preparation of fluvastatin sodium"></PatentFamily><PatentFamily id="917009" number="WO-00192223" title="Process for the preparation of indole derivatives and intermediates of the process"></PatentFamily><PatentFamily id="919219" number="WO-2005058310" title="Use of organic compounds"></PatentFamily><PatentFamily id="921500" number="WO-2006128660" title="Combination of HMG-CoA reductase inhibitors amd mTor inhibitors"></PatentFamily><PatentFamily id="931574" number="RU-02291147" title="[3h]-fluvastatin highly labeled with tritium"></PatentFamily><PatentFamily id="936281" number="WO-2010014502" title="Functionally coated breakable tablets"></PatentFamily><PatentFamily id="959088" number="WO-2009140972" title="Modulation of the Vps10p-domain receptors for the treatment of cardiovascular disease"></PatentFamily><PatentFamily id="967826" number="WO-2007028412" title="Method for producing lactones"></PatentFamily><PatentFamily id="969643" number="IN-200601493" title="Stabilized pharmaceutical composition comprising amorphous fluvastatin"></PatentFamily><PatentFamily id="971076" number="WO-00050574" title="Compositions and methods for modulating serum cholesterol"></PatentFamily><PatentFamily id="97827" number="WO-00017150" title="New salts of HMG-CoA reductase inhibitors"></PatentFamily><PatentFamily id="992668" number="WO-2004105754" title="Nitrooxyderivatives of fluvastatin, pravastatin, cerivastatin, atorvastatin and rosuvastatin as cholesterol-reducing agents with improved anti-inflammatory, antithrombotic and antiplatelet activity"></PatentFamily><PatentFamily id="994272" number="WO-2006048893" title="A process for synthesis of large particle size statin compounds."></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>30</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>22</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>15</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>51</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="4">Delivery device</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>57</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>13</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>14</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pharmathen SA" id="1003489"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Endocrine Health I Goteborg AB" id="1006431"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lunan Pharmaceutical Co Ltd" id="1009275"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sandoz Yakuhin KK Tokyo (SYKK)" id="1010395"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chonnam National University" id="1011650"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Fabbrica Italiana Sintetici SpA" id="1014135"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="GL PharmTech Corp" id="1014242"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of the Punjab" id="1014582"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pharmena Sp zoo" id="1015337"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="IntelliPharmaCeutics International Inc" id="1016256"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mai De Ltd" id="1016832"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="SphingoTec GmbH" id="1017567"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hunan University" id="1017706"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Ulsan" id="1017944"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="ExCRX Singapore Pte Ltd" id="1018770"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Hisun Pharmaceutical Co Ltd" id="1019688"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mitsubishi Chemical Holdings Corp" id="1022450"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="MSN Laboratories Ltd" id="1025511"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Anhui Anke Biotechnology (Group) Co Ltd" id="1027048"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Technion - Israel Institute of Technology" id="1030571"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Fogangren Bio-Pharma Ltd" id="1030649"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Thermo Fisher Scientific Inc" id="1032764"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Canopus BioPharma Inc" id="1033936"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="FUJIFILM Holdings Corp" id="1037804"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing Huaanfo Biomedical Research Centre Inc" id="1039287"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Boréal Pharma Recherche Clinique Inc" id="1039832"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Skåne University Hospital" id="1043316"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Protia LLC" id="1043660"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Asymchem Inc" id="1047484"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Poxel SA" id="1048471"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shenzhen Salubris Pharmaceuticals Co Ltd" id="1053478"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Enaltec Labs Pvt Ltd" id="1053716"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Puyi Chem-Tech Co. Ltd." id="1053795"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Polpharma SA" id="1054012"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="JW Life Science Corp" id="1054500"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="China National Pharmaceutical Group Corporation" id="1055632"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ulkar Holding" id="1057755"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing Anzhen Hospital" id="1058210"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Helvetica Industries Pvt Ltd" id="1060251"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Redx Pharma Plc" id="1060461"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Citech Co Ltd" id="1071576"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hefei Huafang Medical Technology Co Ltd" id="1072314"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Institute of Technology" id="1075365"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Tianlong Pharmaceutical Co Ltd" id="1076507"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Adrenomed AG" id="1076986"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Qidong Dongyue Pharmaceutical Co Ltd" id="1077724"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shiner Pharm Corp" id="1079426"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hetero Group" id="1087006"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="FNG Research Co Ltd" id="1089659"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Xiamen Ants-Bro Technology Co Ltd" id="1093545"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dalana3 Sl" id="1105558"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cipherome Inc" id="1128815"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Xiamen An Pu Dun Information Technology Co. Ltd" id="1144928"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="ISM" id="1145216"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alliance Medical Group" id="1148001"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hummingdoc" id="1149645"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AstraZeneca plc" id="14190"></CompanyLink><CountAsOwner>6</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>8</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BASF SE" id="14356"></CompanyLink><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Boryung Pharm Co Ltd" id="14987"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bristol-Myers Squibb Co" id="15065"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Council of Scientific and Industrial Research (India)" id="15561"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="CSL Ltd" id="15563"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Royal DSM NV" id="15823"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ferrer Internacional SA" id="16118"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Gesparal SA" id="16317"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bausch Health Companies Inc" id="17058"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Italfarmaco SpA" id="17278"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johnson &amp; Johnson" id="17332"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="H Lundbeck A/S" id="17900"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck KGaA" id="18101"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mylan NV" id="18439"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Myriad Genetics Inc" id="18440"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="National Defense Medical Center" id="18459"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="The Procter &amp; Gamble Co" id="19143"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="RIKEN" id="19442"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sumitomo Chemical Co Ltd" id="20268"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"></CompanyLink><CountAsOwner>6</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>7</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Towa Pharmaceutical Co Ltd" id="20423"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johns Hopkins University" id="20596"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Monash University" id="20629"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mount Sinai School of Medicine" id="20631"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Northwestern University" id="20645"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Pennsylvania" id="20658"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Seoul National University" id="20676"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Toronto" id="20688"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Yuhan Corp" id="20984"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Medical College of Wisconsin" id="21040"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>26</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>26</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sigma-Tau Ind Farm Riunite SpA" id="21159"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="OsteoScreen Inc" id="21170"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="USV Pharmaceutical Corp" id="21230"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universite De Montreal" id="21280"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lupin Ltd" id="21932"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="HanAll Biopharma Co Ltd" id="22230"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Galephar PR Inc" id="22408"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Leicester" id="22496"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lonza Group AG" id="22690"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Katholieke Universiteit Leuven" id="23009"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Verenium Corp" id="23095"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"></CompanyLink><CountAsOwner>26</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>26</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="NicOx SA" id="23741"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chinese Academy of Sciences" id="23863"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="St Elizabeths Medical Center of Boston Inc" id="24746"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harvard Medical School" id="24839"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Yonsei University" id="25184"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Lund" id="25208"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universita di Bari" id="25249"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Colorado System" id="25520"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Gothenburg" id="25752"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sun Pharmaceutical Industries Ltd" id="27561"></CompanyLink><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Taro Pharmaceutical Industries Ltd" id="27570"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wockhardt Ltd" id="27614"></CompanyLink><CountAsOwner>7</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>7</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Occupational &amp; Environmental Health" id="27834"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="DURECT Corp" id="27962"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Biocon Ltd" id="28769"></CompanyLink><CountAsOwner>8</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>8</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Clariant International AG" id="28821"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zydus-Cadila Group" id="29062"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Reckitt Benckiser plc" id="29074"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Glenmark Pharmaceuticals Ltd" id="29326"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kimberly-Clark Worldwide Inc" id="29838"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Morepen Laboratories Ltd" id="30185"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="NanoMaterials Technology Pte Ltd" id="31721"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alfred E Tiefenbacher" id="DOL1000198"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Quest Diagnostics Inc" id="DOL1000590"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>